Maryland allows veterinary cannabis consultations

Maryland is set to allow veterinary cannabis consultations beginning October 1, 2026, after enactment of House Bill 452, a measure that protects licensed veterinarians from state discipline solely for discussing or recommending cannabis or CBD products for animal patients. Signed into law on April 14, 2026, the bill adds a narrow but important safeguard to Maryland practice law: veterinarians can talk with clients about these products without that conversation itself becoming grounds for board action. (mgaleg.maryland.gov)

The legislation arrives as more pet parents ask veterinarians about cannabinoids for pain, mobility, seizures, anxiety, and palliative support, while many clinicians have operated in a gray zone. Maryland’s bill does not create an animal cannabis prescribing system, nor does it establish approved veterinary cannabis products. Instead, it addresses professional risk by limiting how the State Board of Veterinary Medical Examiners can respond when a veterinarian discusses or recommends cannabis-related options. Today’s Veterinary Business described Maryland as the fifth state to adopt this kind of protection, reflecting a broader national trend toward allowing fact-based veterinary conversations even in the absence of uniform federal rules. (todaysveterinarybusiness.com)

The statutory language is specific. HB 452 says the board may not suspend or revoke a license, reprimand or censure a licensee, or place a licensee on probation solely because the veterinarian discussed or recommended cannabis, as defined in Maryland law, or a product containing cannabidiol for an animal’s potential therapeutic effect or health supplementation purposes. The bill moved quickly through the 2026 session, passed the Senate 43-0 on April 8, 2026, and was approved by the governor six days later. Supportive testimony submitted on behalf of the Maryland Veterinary Medical Association framed the measure as a way to let veterinarians discuss cannabis for animal health concerns without fear of punishment. (mgaleg.maryland.gov)

That support came with caveats. In written testimony, cannabis attorney J. Cohen Roth argued that the bill would improve animal welfare and public safety by letting veterinarians provide guidance, but said the language could be refined to better align with Maryland’s cannabis framework and to make the veterinarian’s role clearer. Roth also urged lawmakers to more explicitly ground cannabis guidance in the veterinarian-client-patient relationship, a point that may resurface if regulators or lawmakers revisit implementation details. (mgaleg.maryland.gov)

The bigger constraint is still federal and scientific, not state-level speech. FDA says it has not approved cannabis-derived products for use in animals, and it has warned that CBD products marketed for animals may raise concerns about safety, quality, contamination, adverse events, and drug interactions. The agency has also specifically said CBD in animal products does not currently satisfy the criteria for generally recognized as safe status. At the same time, FDA has been gathering public input on cannabis-derived products in veterinary medicine, underscoring that use in practice is outpacing the regulatory framework. A frequently cited review in the veterinary literature likewise found growing interest, but limited evidence and ongoing concerns about inconsistent product quality and THC contamination. (fda.gov)

Why it matters: For veterinary teams, Maryland’s move is best understood as a risk-management and client-communication change. It gives clinicians more room to meet pet parent demand with evidence-aware counseling instead of silence, which could help reduce unsafe self-directed use of retail products. It may also push more hospitals to formalize how they document cannabis conversations, screen for concurrent medications, discuss toxicosis risk, and set expectations around uncertain efficacy. But the law does not solve core clinical challenges: there is still no FDA-approved veterinary cannabis product, no uniform dosing framework, and no consistent national standard for product quality or labeling. (mgaleg.maryland.gov)

For practice leaders, that means the operational questions now matter as much as the legal ones. Clinics may need internal protocols on who can counsel clients, what can be documented in the medical record, how to distinguish discussion from prescribing, and how to handle products bought outside traditional veterinary distribution channels. Maryland regulations already govern broader veterinary practice standards, but HB 452 itself does not appear to answer those workflow questions in detail, leaving room for board guidance or professional association education to shape how the law works on the ground. (regs.maryland.gov)

What to watch: The next signals will likely come from implementation rather than legislation, including any guidance from the Maryland board, educational materials from organized veterinary groups, and continued federal activity as FDA reviews comments on cannabis-derived products in animals. If demand from pet parents keeps rising, Maryland could face pressure to clarify VCPR requirements, documentation standards, and product-related guardrails beyond the narrow disciplinary protection now taking effect. (fda.gov)